Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : PXS-5505,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : University of Rochester
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Clears Pharmaxis Cancer Drug to Progress to Phase 2 Study in Liver Cancer
Details : PXS‐5505 has progressed to a phase 2 clinical trial looking for evidence of disease modifying effects in the bone cancer myelofibrosis as a monotherapy so exploring its additional potential to address cancers where fibrosis is limiting the clinical ben...
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 09, 2021
Lead Product(s) : PXS-5505,Atezolizumab,Bevacizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : University of Rochester
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
Details : PXS‐5505 is currently progressing well through a phase 1c/2 clinical trial looking for evidence of disease modifying effects in bone cancer myelofibrosis as a monotherapy.
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 05, 2021
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Parexel Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Pharmaxis Commences Final Cohort Dosing in Bone Marrow Cancer Phase 1c Trial
Details : The phase 1c/2a trial MF‐101 aims to demonstrate that PXS‐5505 is safe and effective as a monotherapy in myelofibrosis patients who are intolerant, unresponsive or ineligible for treatment with approved JAK inhibitor drugs.
Brand Name : PXS-5505
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 04, 2021
Lead Product(s) : PXS-5505
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Parexel Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?